Daiichi Sankyo, AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201); Total Payments by AstraZeneca to Daiichi Could Reach $6.9B